SACT 1 - Inaugural Event 6^th Jan 2023

International Speaker	Talk Title	Highlights
Dr. Nirali N. Shah Cancer Research National Cancer Institute	CART Cell Therapy : Factor affecting Clinical Outcome in B Cell Malignancies	A talk on different factors effects on B-cell malignancies already have a compromised or dysregulated immune system. Different approaches for overcoming those factors.
Dr. Rizwan Romee Dana-Farber Cancer Institute	Next Generation Cell Therapies for Cancer : NK & CAR -NK Cells	Modern way of developing CAR constructs contain one or more co-stimulatory domains which improve T-cell activation and persistence for treating of cancer cells.
Dr. Mingming Li Cytiva	Pre-Clinical to Commercialization : A Systematic Platform and Pathway Based Approach for CAR-T Therapies	CAR T cell therapy have been successful in treating of hematologic malignancies. In which targeting of CD19, a surface antigen expressed on precursor and mature B cells, can treat B cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clinical trials in which evaluating new CAR-T cell therapies against different types of cancers, detailing the latest trends in CAR-T cell development.
Dr. Mahender Rao Stempeutics	"Off the shelf" Universal Cell therapy using iPSC-derived rejuvenated Immune cells for solid and liquid tumors	iPS cells are delivered from own patients cells further use for creating the cells that has potential to replicate the tissue affected by disease. This technique helps for study different test related to drug efficacy, side effects, and toxicity and to develop new drugs and therapies.

National Speaker	Talk Title	Highlights
Dr. Arun Kumar Arunachalam Christian Medical College, Vellore	Current Manufacturing methods for the large-scale production of Clinical-Grade Virus-Specific T Cells for phase I/II clinical trials	The SB transposon/transposase are used to produce genetically modified CAR-T cells for phase I/II clinical trial, Transfected T cells are subsequently expanded on artificial antigen-presenting cells. The major advantage of using the SB system are clinical-grade plasmids which are simpler to produce, cost effectiveness Also cell products genetically modified with gamma retroviral or lentiviral vectors are also used in for manufacturing of CAR T-Cell.
Dr. Likhesh Sharma Cytiva Dr. Kunapuli Kishore Pulse Pharmaceuticals	Challenges of Process Development in Cell Therapy Products	In cell therapy process challenging because of the difficulty of fully characterizing a living cell and obtaining relevant data in real time.
Dr. T Rajkumar Adyar Cancer Institute Dr. Rajiv Sarin TATA Memorial Hospital Dr. Balaram Rao Aurigene Discovery Technologies Dr. Madhvi Rao BIRAC	Unlocking the Power of Collaboration to Fuel Cell Therapy Development in India	The objective of this cooperative endeavour is to progress the domains of clinical investigation and advancement concerning mesenchymal stem cell and NK cell therapy. The collaboration represents a critical advancement in the search for cutting-edge medical treatments.
Dr. Uday Kumar Stempeutics	Robust and stringent Quality Control/Analytical Characterization for Cell Therapy Products - Streamlining Strategy from IND to Clinical	Analytical development in cell therapy involves the development and optimization of methods and tools to evaluate the quality, safety, and efficacy of cell-based products
Shalini Jatia ImPaCCT Foundation	Celebrating Victory over Cancer	"Hope" is the biggest annual event for Pediatric Cancer patients at Tata Memorial Centre. "Hope" as the word signifies, is a strong and positive belief of victory over. childhood cancer. It is a celebration to spread the message in the society and country that "Childhood Cancer is Curable".